1. Home
  2. PHAT

as 08-22-2025 4:00pm EST

$
-
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Founded: 2018 Country:
United States
United States
Employees: N/A City: FLORHAM PARK
Market Cap: 716.5M IPO Year: 2019
Target Price: $16.40 AVG Volume (30 days): 1.1M
Analyst Decision: Strong Buy Number of Analysts: 5
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -4.71 EPS Growth: N/A
52 Week Low/High: $2.21 - $19.71 Next Earning Date: 08-07-2025
Revenue: $114,039,000 Revenue Growth: 1049.82%
Revenue Growth (this year): 194.4% Revenue Growth (next year): 103.23%

PHAT Daily Stock ML Predictions

Share on Social Networks: